Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units

V. Vojtová, M. Kolár, K. Hricová, R. Uvízl, J. Neiser, L. Blahut, K. Urbánek,

. 2011 ; 34 (3) : 291-8. [pub] 20110730

Language English Country Italy

Document type Journal Article, Research Support, Non-U.S. Gov't

Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.

000      
00000naa a2200000 a 4500
001      
bmc12027459
003      
CZ-PrNML
005      
20121210111327.0
007      
ta
008      
120817e20110730it f 000 0#eng||
009      
AR
035    __
$a (PubMed)21811750
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Vojtová, Vladimíra $u Department of Pharmacology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Czech Republic.
245    10
$a Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units / $c V. Vojtová, M. Kolár, K. Hricová, R. Uvízl, J. Neiser, L. Blahut, K. Urbánek,
520    9_
$a Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.
650    _2
$a amikacin $x farmakologie $7 D000583
650    _2
$a antibakteriální látky $x farmakologie $7 D000900
650    _2
$a cefoperazon $x farmakologie $7 D002438
650    _2
$a ceftazidim $x farmakologie $7 D002442
650    _2
$a ciprofloxacin $x farmakologie $7 D002939
650    _2
$a mnohočetná bakteriální léková rezistence $7 D024901
650    _2
$a gentamiciny $x farmakologie $7 D005839
650    _2
$a jednotky intenzivní péče $7 D007362
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a kyselina penicilanová $x analogy a deriváty $x farmakologie $7 D010397
650    _2
$a piperacilin $x farmakologie $7 D010878
650    _2
$a Pseudomonas aeruginosa $x účinky léků $7 D011550
650    _2
$a sulbaktam $x farmakologie $7 D013407
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kolár, Milan
700    1_
$a Hricová, Kristýna
700    1_
$a Uvízl, Radek
700    1_
$a Neiser, Jan
700    1_
$a Blahut, Ladislav
700    1_
$a Urbánek, Karel
773    0_
$w MED00005605 $t The new microbiologica $x 1121-7138 $g Roč. 34, č. 3 (20110730), s. 291-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21811750 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121210111404 $b ABA008
999    __
$a ok $b bmc $g 949501 $s 784805
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 34 $c 3 $d 291-8 $e 20110730 $i 1121-7138 $m The New microbiologica $n New Microbiol $x MED00005605
LZP    __
$a Pubmed-20120817/11/03

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...